Zoetis Inc. $ZTS Shares Sold by Bokf Na

Key Points

• Bokf Na cut its Zoetis stake by 35.2% in the third quarter, selling 13,050 shares and retaining 24,011 shares valued at approximately $1.68 million. Institutional investors and hedge funds collectively own 92.8% of the company.
• Analyst sentiment remains mixed, with six Buy ratings, twelve Holds and one Sell; Zoetis has an overall consensus rating of Hold and an average price target of $93.79.
• Zoetis shares opened at $79.67, while the company reported quarterly EPS of $1.87, slightly above estimates, and declared a quarterly dividend of $0.53, equivalent to a 2.7% yield.

Bokf Na reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 35.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 24,011 shares of the company's stock after selling 13,050 shares during the period. Bokf Na's holdings in Zoetis were worth $1,677,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its holdings in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company's stock worth $73,000 after buying an additional 91 shares in the last quarter. Lipe & Dalton increased its holdings in Zoetis by 2.2% in the first quarter. Lipe & Dalton now owns 4,698 shares of the company's stock valued at $555,000 after buying an additional 102 shares in the last quarter. Root Financial Partners LLC increased its holdings in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after buying an additional 103 shares in the last quarter. Valmark Advisers Inc. raised its position in shares of Zoetis by 7.7% in the first quarter. Valmark Advisers Inc. now owns 1,747 shares of the company's stock worth $207,000 after acquiring an additional 125 shares during the period. Finally, Balefire LLC raised its position in shares of Zoetis by 6.7% in the first quarter. Balefire LLC now owns 1,996 shares of the company's stock worth $236,000 after acquiring an additional 125 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. UBS Group increased their target price on shares of Zoetis from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Tuesday. Morgan Stanley reduced their price target on Zoetis from $85.00 to $82.00 and set an "overweight" rating for the company in a report on Thursday. BNP Paribas Exane reduced their price target on Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday, August 11th. BTIG Research dropped coverage on Zoetis in a research report on Friday. They set a "buy" rating on the stock. Finally, Zacks Research raised Zoetis from a "strong sell" rating to a "hold" rating in a report on Monday, October 26th. Six research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $93.79.

Zoetis Trading Up 1.1%

Shares of Zoetis stock opened at $79.67 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $144.83. The firm has a market capitalization of $32.92 billion, a PE ratio of 13.13, a P/E/G ratio of 1.18 and a beta of 0.74. The firm's 50-day moving average price is $75.04 and its 200 day moving average price is $93.64.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the business earned $1.76 EPS. Zoetis's quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.15 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis's dividend payout ratio (DPR) is currently 34.93%.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company's product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.